Truist lowered the firm’s price target on Praxis Precision (PRAX) to $85 from $175 and keeps a Buy rating on the shares. The firm is removing ulixacaltamide in essential tremor, ET, sales from its model after the company disclosed last week that Independent Data Monitoring Committee recommended that its study be stopped for futility due to the results being unlikely to meet the primary efficacy endpoint, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision price target lowered to $120 from $170 at Guggenheim
- Praxis Precision price target lowered to $85 from $150 at Needham
- Praxis Precision price target lowered to $73 from $117 at Baird
- Praxis Precision Medicines: A Compelling Buy Amidst Promising Pipeline Developments
- Praxis Precision price target lowered to $105 from $120 at H.C. Wainwright